Roivant in-licenses HanAll's autoimmune candidate

HanAll Biopharma Co. Ltd. (KOSDAQ:009420) granted Roivant Sciences GmbH (Basel, Switzerland) exclusive rights to develop and commercialize HL161

Read the full 185 word article

User Sign In